Charles M. Conway

2.3k total citations · 3 hit papers
47 papers, 1.6k citations indexed

About

Charles M. Conway is a scholar working on Psychiatry and Mental health, Pathology and Forensic Medicine and Cellular and Molecular Neuroscience. According to data from OpenAlex, Charles M. Conway has authored 47 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Psychiatry and Mental health, 14 papers in Pathology and Forensic Medicine and 12 papers in Cellular and Molecular Neuroscience. Recurrent topics in Charles M. Conway's work include Migraine and Headache Studies (37 papers), Trigeminal Neuralgia and Treatments (13 papers) and Neuropeptides and Animal Physiology (10 papers). Charles M. Conway is often cited by papers focused on Migraine and Headache Studies (37 papers), Trigeminal Neuralgia and Treatments (13 papers) and Neuropeptides and Animal Physiology (10 papers). Charles M. Conway collaborates with scholars based in United States, Germany and United Kingdom. Charles M. Conway's co-authors include Robert Croop, Richard B. Lipton, Vladimir Coric, Elyse Stock, Peter J. Goadsby, David Stock, Gene M. Dubowchik, David Kudrow, Peter C. Isakson and Camilla I. Svensson and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Neuroscience.

In The Last Decade

Charles M. Conway

45 papers receiving 1.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial

2019 276 citations Robert Croop, Peter J. Goadsby et al. The Lancet profile →
Rimegepant, an Oral Calcitonin Gene–Related Peptide Receptor Antagonist, for Migraine

2019 265 citations Richard B. Lipton, Robert Croop et al. profile →
Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial

2020 233 citations Robert Croop, Richard B. Lipton et al. The Lancet profile →

Peers

Countries citing papers authored by Charles M. Conway

Since Specialization

Citations

This map shows the geographic impact of Charles M. Conway's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Charles M. Conway with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Charles M. Conway more than expected).

Fields of papers citing papers by Charles M. Conway

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Charles M. Conway. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Charles M. Conway. The network helps show where Charles M. Conway may publish in the future.

Co-authorship network of co-authors of Charles M. Conway

This figure shows the co-authorship network connecting the top 25 collaborators of Charles M. Conway. A scholar is included among the top collaborators of Charles M. Conway based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Charles M. Conway. Charles M. Conway is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Rimegepant is Safe and Tolerable for the Acute Treatment of Migraine in Patients Using Preventive Migraine Medications: Results from a Long-Term Open-Label Safety Study (2370) 2021 ·Neurology ·Jack Schim, Susan Hutchinson, Richard B. Lipton, Robert Croop, Elyse Stock, Alexandra Thiry, Charles M. Conway, Meghan Lovegren, Vlad Coric, (unknown)	4
2	Long-term Use of Rimegepant 75 mg for the Acute Treatment of Migraine Reduces Use of Analgesics and Antiemetics (5072) 2021 ·Neurology ·David Kudrow, Kathleen Mullin, Gary Berman, Richard B. Lipton, (unknown), Alexandra Thiry, Meghan Lovegren, Charles M. Conway, Vlad Coric, Robert Croop	2
3	Preference for Rimegepant and Improved Clinical Global Impression of Change Among Adults With a History of Triptan Treatment Failure: Results from a Long-Term Open-Label Safety Study (5084) 2021 ·Neurology ·Ira Turner, Jelena Pavlović, Richard B. Lipton, (unknown), Alexandra Thiry, Meghan Lovegren, Charles M. Conway, Vlad Coric, Robert Croop	1
4	Calcitonin gene-related peptide (CGRP) receptor antagonists: Heterocyclic modification of a novel azepinone lead 2021 ·Bioorganic & Medicinal Chemistry Letters ·Guanglin Luo, (unknown), Ling Chen, Charles M. Conway, Michael Gulianello, Walter A. Kostich, (unknown), Laura J. Signor, Ping Chen, Carl D. Davis, Valerie Whiterock, Richard Schartman, (unknown), John E. Macor, Gene M. Dubowchik	2
5	Acute Treatment of Migraine with Rimegepant Improves Health Related Quality of Life in Adults With a History of Triptan Treatment Failure: Results from a Long-Term, Open-Label Safety Study (5029) 2021 ·Neurology ·Ira Turner, Paul Winner, Richard B. Lipton, (unknown), Gilbert L’Italien, Alexandra Thiry, Meghan Lovegren, Charles M. Conway, Vlad Coric, Robert Croop	1
6	Rimegepant is Effective for the Acute Treatment of Migraine in Subjects Taking Concurrent Preventive Medication: Results From 3 Phase 3 Trials (2091) 2020 ·Neurology ·Jelena Pavlović, David W. Dodick, Lawrence C. Newman, Richard B. Lipton, Elyse Stock, Alexandra Thiry, Charles M. Conway, (unknown), Beth Morris, Vladimir Coric, Robert Croop	1
7	Cardiovascular Safety of Rimegepant 75 mg in 3 Randomized Clinical Trials and Systematic Evaluations from In Vitro, Ex Vivo, and In Vivo Nonclinical Assays (2141) 2020 ·Neurology ·Charles M. Conway, Robert Croop, Gene M. Dubowchik, Vladimir Coric, Richard B. Lipton	12
8	Rimegepant 75 mg Demonstrates Safety and Tolerability Similar to Placebo With No Effects of Age, Sex, or Race in 3 Phase 3 Trials (1609) 2020 ·Neurology ·Jack Schim, Susan Hutchinson, Richard B. Lipton, Elyse Stock, Alexandra Thiry, Charles M. Conway, (unknown), Beth Morris, Vladimir Coric, Robert Croop	1
9	Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial breakdown → 2020 ·The Lancet ·Robert Croop, Richard B. Lipton, David Kudrow, David Stock, Lisa Kamen, Charles M. Conway, Elyse Stock, Vladimir Coric, Peter J. Goadsby	233
10	Long-Term Safety of Rimegepant 75 mg for the Acute Treatment of Migraine (Study 201) (4829) 2020 ·Neurology ·Robert Croop, Gary Berman, David Kudrow, Kathleen Mullin, Elyse Stock, Alexandra Thiry, Charles M. Conway, (unknown), Meghan Lovegren, Vladimir Coric, Richard B. Lipton	10
11	Azepino-indazoles as calcitonin gene-related peptide (CGRP) receptor antagonists 2020 ·Bioorganic & Medicinal Chemistry Letters ·Stephen E. Mercer, (unknown), Charles M. Conway, Deborah A. Cook, Carl D. Davis, Sokhom S. Pin, (unknown), Richard Schartman, Laura J. Signor, (unknown), Valerie Whiterock, Ping Chen, Cen Xu, John J. Herbst, Walter A. Kostich, George Thalody, John E. Macor, Gene M. Dubowchik	16
12	Rimegepant 75 mg Demonstrates Superiority to Placebo on Nausea Freedom: Results from a Post Hoc Pooled Analysis of 3 Phase 3 Trials in the Acute Treatment of Migraine (2402) 2020 ·Neurology ·Peter McAllister, Gary Berman, David Kudrow, Timothy R. Smith, Richard B. Lipton, Elyse Stock, David Stock, Charles M. Conway, (unknown), Beth Morris, Vladimir Coric, Robert Croop	1
13	Patient Preference and Improved Clinical Global Impression of Change with Rimegepant for the Acute Treatment of Migraine: Results from a Long-Term Open-Label Safety Study (Study 201) (2112) 2020 ·Neurology ·(unknown), Robert Croop, Richard B. Lipton, Elyse Stock, Alexandra Thiry, Charles M. Conway, Meghan Lovegren, Vladimir Coric, Gilbert L’Italien	0
14	Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial breakdown → 2019 ·The Lancet ·Robert Croop, Peter J. Goadsby, David Stock, Charles M. Conway, Micaela Forshaw, Elyse Stock, Vladimir Coric, Richard B. Lipton	276
15	Inhibition Mediated by Glycinergic and GABAergic Receptors on Excitatory Neurons in Mouse Superficial Dorsal Horn Is Location-Specific but Modified by Inflammation 2017 ·Journal of Neuroscience ·Tomonori Takazawa, Papiya Choudhury, Chi‐Kun Tong, Charles M. Conway, Grégory Scherrer, Pamela Flood, Jun Mukai, Amy B. MacDermott	49
16	Synthesis and SAR of calcitonin gene-related peptide (CGRP) antagonists containing substituted aryl-piperazines and piperidines 2016 ·Bioorganic & Medicinal Chemistry Letters ·Rita L. Civiello, Xiaojun Han, Brett R. Beno, (unknown), John J. Herbst, Cen Xu, Charles M. Conway, John E. Macor, Gene M. Dubowchik	4
17	The synthesis and SAR of calcitonin gene-related peptide (CGRP) receptor antagonists derived from tyrosine surrogates. Part 2 2013 ·Bioorganic & Medicinal Chemistry Letters ·Xiaojun Han, Rita L. Civiello, Charles M. Conway, Deborah A. Cook, Carl D. Davis, Andrew P. Degnan, (unknown), (unknown), Neil Mathias, Paul Moench, Sokhom S. Pin, Richard Schartman, Laura J. Signor, George Thalody, (unknown), Valerie Whiterock, Cen Xu, John E. Macor, Gene M. Dubowchik	7
18	Discovery of BMS-846372, a Potent and Orally Active Human CGRP Receptor Antagonist for the Treatment of Migraine 2012 ·ACS Medicinal Chemistry Letters ·Guanglin Luo, Ling Chen, Charles M. Conway, Rex Denton, (unknown), Michael Gulianello, Yanling Huang, Walter A. Kostich, Kimberley A. Lentz, Stephen E. Mercer, Richard Schartman, Laura J. Signor, (unknown), John E. Macor, Gene M. Dubowchik	32
19	Oxime Carbamate—Discovery of a series of novel FAAH inhibitors 2009 ·Bioorganic & Medicinal Chemistry Letters ·S.Y. Sit, Charles M. Conway, Kai Xie, Robert L. Bertekap, Clotilde Bourin, Kevin D. Burris	23
20	Interactions between nicardipine and enflurane, isoflurane, and sevoflurane 1997 ·Canadian Journal of Anesthesia/Journal canadien d anesthésie ·Tomoki Nishiyama, Takashi Matsukawa, Kazuo Hanaoka, Charles M. Conway	17

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact